Another Alzheimer's Drug Fails as Lilly, Astra Halt Tests
- Lanabecestat was unlikely to meet goals of advanced studies
- Both drugmakers reiterate guidance, see no financial impact
This article is for subscribers only.
Eli Lilly & Co. and AstraZeneca Plc ended two late-stage trials of an experimental drug for Alzheimer’s disease after the treatment failed to show any signs of working, adding to a litany of disappointments for the memory-robbing illness.
An independent data-monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease, the companies said in a statement Tuesday. There were no safety concerns, they said.